OCUP News and Press, Ocuphire Pharma Inc Com From 08/05/21

Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications. The company recently announced positive topline results for its lead candidate, Nyxol, in a Phase 3 study for Reversal of Mydriasis (RM)...

Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases Phase 2 Data from ZETA-1 Trial in Diabetic Retinopathy Expected in 2022 ...

Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas Ocuphire Presenting Nyxol ® + Low Dose Pilocarpine Phase 2 Data in the Presbyopia Industry Panel at E...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc (NASDAQ: OCUP) Surges After VEGA-1 Phase 2 Trial Met Study Endpoints In Presbyopic Patients ” Ocuphire Pharma, Inc. (NASDAQ: OCUP) ...

Gainers: Ocuphire Pharma (OCUP) +26%, Predictive Oncology (POAI) +21%, Verve Therapeutics (VERV) +21%, HUTCHMED (China) (HCM) +21%, Intellia Therapeutics (NTLA) +19%.Losers: Altimmune (ALT) -36%, electroCore (ECOR) -28%,&#x...

Ocuphire Pharma (OCUP) +71% after Phase 2 VEGA-1 trial in presbyopia meets endpoints.Vertex Energy (VTNR) +43% as Clean Harbors to acquire  certain assets.Verb Technology Company (VERB) +37%.Bridgeline Digital (BLIN) +29%.AST SpaceMobile (ASTS) +22%.Exela Technologies (XELA) +2...

Ocuphire Pharma (OCUP) soars 71% premarket after announcing results from Phase 2 VEGA-1 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine ((LDP)) in presbyopic subjects successfully met its primary and many secondary endpoints. High...

Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol ® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision Key secondary endpoints on visual acuity and pupil diameter showed...

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has entered into a licensing agreement with Ocuphire Pharma Inc. (NASDAQ: OCUP) . Under the agreem...

Processa Pharmaceuticals (PCSA) has entered into a licensing agreement with Ocuphire Pharma (OCUP), up 4% premarket to license in RX-3117.Processa will evaluate the potential benefit of RX-3117 for patients with pancreatic or non-small cell lung cancer. Under the terms of the agreem...